PTSM: Pharmaceutical Technology Sourcing and Management
Almac partnered with Optel Vision to provide a line-level solution (hardware and software) integrated with Almac’s proprietary level three, site-level software.
Almac Group, a global contract development and manufacturing organization, announced on April 25, 2016 its plans to expand serialization capabilities to include its United States commercial packaging facility in Audubon, PA. Building upon Almac’s in-house proprietary serialization/track-and-trace solution developed at its United Kingdom headquarters, this technology expansion will address FDA regulations, meeting the requirements outlined in the Drug Quality and Security Act, the company said in a press announcement. Almac partnered with Optel Vision to provide a line-level solution (hardware and software) integrated with Almac’s proprietary level three, site-level software. This new serialization solution is a high-spec standalone line that prints, verifies, and aggregates saleable packs to the pallet with reporting functionality.
“We knew Almac had its own in-house solution for the UK and for the first Almac serialization project in the US, we combined the knowledge of both companies to design a solution that meets Almac quality standards as well as the demand from global markets using the Optel Vision hardware and software solutions, said Yvon Lemay, Optel Vision project manager. “The system is now operational and can be easily scalable for future needs.”
Source: Almac
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.